These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 29450755)

  • 21. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
    Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric Cancer.
    Satake H; Kondo M; Mizumoto M; Kotake T; Okita Y; Ogata T; Hatachi Y; Yasui H; Miki A; Imai Y; Ichikawa C; Murotani K; Kotaka M; Kato T; Kaihara S; Tsuji A
    Anticancer Res; 2017 Jul; 37(7):3703-3710. PubMed ID: 28668863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
    Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
    Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 25. [A case of mediastinal lymph node gastric cancer recurrence during S-1 adjuvant therapy successfully treated with cisplatin + capecitabine as second-line chemotherapy].
    Hirata A; Itatsu K; Fukaya M; Ebata T; Yokoyama Y; Tsunoda N; Igami T; Sugawara G; Uehara K; Yoshioka Y; Usui H; Nagino M
    Gan To Kagaku Ryoho; 2013 Apr; 40(4):519-22. PubMed ID: 23848024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
    Wang Y; Zhuang RY; Yu YY; Yu S; Hou J; Ji Y; Sun YH; Shen KT; Shen ZB; Liu FL; Zhao NQ; Liu TS
    Oncotarget; 2016 Nov; 7(46):76298-76307. PubMed ID: 27602586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
    Lee J; Lim DH; Kim S; Park SH; Park JO; Park YS; Lim HY; Choi MG; Sohn TS; Noh JH; Bae JM; Ahn YC; Sohn I; Jung SH; Park CK; Kim KM; Kang WK
    J Clin Oncol; 2012 Jan; 30(3):268-73. PubMed ID: 22184384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
    Kim SM; An JY; Lee J; Sohn TS; Kim S
    Ann Surg Oncol; 2018 Jun; 25(6):1616-1624. PubMed ID: 29569127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [CURRENT STATE OF ADJUVANT TREATMENT FOR GASTRIC CANCER AFTER RADICAL SURGERY WITH EXTENDED LYMPH NODE DISSECTION].
    Skoropad VY
    Vopr Onkol; 2015; 61(3):339-45. PubMed ID: 26242143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective study of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric cancer.
    Li N; Wu H; Xu X; Wei Q; Ding Y; Liu S; Wu J; Zheng Y; Xu N; Gao Y; Jiang H
    Sci Rep; 2024 Jul; 14(1):15150. PubMed ID: 38956232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial.
    Zhao Q; Lian C; Huo Z; Li M; Liu Y; Fan L; Tan B; Zhao X; Zhang Z; Wang D; Liu Y; Guo H; Yang P; Tian Y; Li Y
    Cancer Med; 2020 Aug; 9(16):5731-5745. PubMed ID: 32583567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Present state and prospects of adjuvant chemotherapy for gastric cancer].
    Hori T; Ozawa R; Hanayama H; Yamashita H; Kaibe N; Matsumoto T; Oshima T; Takemura M; Kikuchi S; Sasako M
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1390-5. PubMed ID: 21918333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study.
    Mizushima T; Ikeda M; Kato T; Ikeda A; Nishimura J; Hata T; Matsuda C; Satoh T; Mori M; Doki Y
    BMC Cancer; 2019 Sep; 19(1):929. PubMed ID: 31533662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
    Kano M; Hayano K; Hayashi H; Hanari N; Gunji H; Toyozumi T; Murakami K; Uesato M; Ota S; Matsubara H
    Ann Surg Oncol; 2019 Jun; 26(6):1805-1813. PubMed ID: 30977014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
    Chongqing T; Liubao P; Xiaohui Z; Jianhe L; Xiaomin W; Gannong C; Siying W; Lihui O; Ziying Z
    Pharmacoeconomics; 2014 Mar; 32(3):235-43. PubMed ID: 23709451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy and safety of adjuvant immunotherapy (Tislelizumab) plus chemotherapy vs. adjuvant chemotherapy alone in lymph node-positive patients with gastric cancer after D2 radical resection: a prospective, 2-arm, phase II study.
    Shi JW; Zhou Y; Wu S
    Eur Rev Med Pharmacol Sci; 2023 Nov; 27(21):10472-10480. PubMed ID: 37975371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Timing of initiation of adjuvant chemotherapy for gastric cancer: A case-matched comparison study of laparoscopic vs. open surgery.
    Kaito A; Kinoshita T; Shitara K; Shibasaki H; Nishida T
    Eur J Surg Oncol; 2017 Apr; 43(4):801-807. PubMed ID: 28187877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience.
    Yen HH; Chen CN; Yeh CC; Lai IR
    World J Surg Oncol; 2021 Apr; 19(1):124. PubMed ID: 33865416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.
    Tsuburaya A; Mizusawa J; Tanaka Y; Fukushima N; Nashimoto A; Sasako M;
    Br J Surg; 2014 May; 101(6):653-60. PubMed ID: 24668391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.